Literature DB >> 25644029

Cognitive performances and DAT imaging in early Parkinson's disease with mild cognitive impairment: a preliminary study.

M T Pellecchia1, M Picillo, G Santangelo, K Longo, M Moccia, R Erro, M Amboni, C Vitale, C Vicidomini, M Salvatore, P Barone, S Pappatà.   

Abstract

OBJECTIVES: Mild cognitive impairment (MCI) is a common feature in Parkinson's disease (PD). We performed an exploratory study to investigate dopaminergic nigrostriatal innervation and its cognitive correlates in early untreated PD patients with MCI as compared to cognitively intact patients. PATIENTS AND METHODS: A consecutive series of 34-de-novo, drug-naïve patients with PD were enrolled. They underwent [123-I] FP-CIT SPECT and comprehensive neuropsychological battery. MCI was identified in 15 of 34 patients with PD.
RESULTS: The two groups did not show any statistically significant difference in age, sex, disease duration, education, lateralization, and H&Y and Hospital Anxiety and Depression Scale scores. Logistic regression analysis showed that UPDRS-III was weakly associated with MCI (P = 0.034). Partial correlation analysis controlling for UPDRS-III and age suggested that in PD patients with MCI reduced V3″ values in the more affected caudate were correlated with reduced performances in frontal assessment battery, Trail Making Test: part B minus Part A and copy task of the Rey-Osterrieth complex figure test. Reduced V3″ values in the more and less affected putamen were significantly related with reduced performance in frontal assessment battery and in copy task of Rey-Osterrieth complex figure test, respectively. No correlation was found between neuropsychological scores and DAT availability in PD patients without MCI.
CONCLUSIONS: Although preliminary, our results suggest that striatal dopamine depletion may contribute to some cognitive deficit in early never treated PD patients with MCI.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  SPECT; cognition; dopamine transporter; early Parkinson's disease; mild cognitive impairment

Mesh:

Substances:

Year:  2015        PMID: 25644029     DOI: 10.1111/ane.12365

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  16 in total

1.  Serotonin, β-amyloid, and cognition in Parkinson disease.

Authors:  Vikas Kotagal; Cathie Spino; Nicolaas I Bohnen; Robert Koeppe; Roger L Albin
Journal:  Ann Neurol       Date:  2018-05-11       Impact factor: 10.422

2.  Cognitive performance correlates with the degree of dopaminergic degeneration in the associative part of the striatum in non-demented Parkinson's patients.

Authors:  Dorothee Kübler; Henning Schroll; Ralph Buchert; Andrea A Kühn
Journal:  J Neural Transm (Vienna)       Date:  2017-06-22       Impact factor: 3.575

3.  Striatal Dopaminergic Depletion Pattern Reflects Pathological Brain Perfusion Changes in Lewy Body Diseases.

Authors:  Yu Iwabuchi; Tohru Shiga; Masashi Kameyama; Raita Miyazawa; Morinobu Seki; Daisuke Ito; Hiroyuki Uchida; Hajime Tabuchi; Masahiro Jinzaki
Journal:  Mol Imaging Biol       Date:  2022-06-14       Impact factor: 3.488

4.  Path analysis of biomarkers for cognitive decline in early Parkinson's disease.

Authors:  Dmitri K Gramotnev; Galina Gramotnev; Alexandra Gramotnev; Mathew J Summers
Journal:  PLoS One       Date:  2022-05-13       Impact factor: 3.752

5.  Effects of dopaminergic drug adjustment on executive function in different clinical stages of Parkinson's disease.

Authors:  Hidetomo Murakami; Tetsuhito Nohara; Hidenobu Shozawa; Yoshiyuki Owan; Takeshi Kuroda; Satoshi Yano; Machiko Kezuka; Mitsuru Kawamura; Kenjiro Ono
Journal:  Neuropsychiatr Dis Treat       Date:  2017-10-25       Impact factor: 2.570

6.  Presynaptic dopaminergic terminal imaging and non-motor symptoms assessment of Parkinson's disease: evidence for dopaminergic basis?

Authors:  M A Qamar; A Sauerbier; M Politis; H Carr; P Loehrer; K Ray Chaudhuri
Journal:  NPJ Parkinsons Dis       Date:  2017-01-25

Review 7.  Assessing Executive Dysfunction in Neurodegenerative Disorders: A Critical Review of Brief Neuropsychological Tools.

Authors:  Helena S Moreira; Ana S Costa; São L Castro; César F Lima; Selene G Vicente
Journal:  Front Aging Neurosci       Date:  2017-11-09       Impact factor: 5.750

Review 8.  Mild Cognitive Impairment in Parkinson's Disease-What Is It?

Authors:  Rimona S Weil; Alyssa A Costantini; Anette E Schrag
Journal:  Curr Neurol Neurosci Rep       Date:  2018-03-10       Impact factor: 5.081

Review 9.  Can neuroimaging predict dementia in Parkinson's disease?

Authors:  Juliette H Lanskey; Peter McColgan; Anette E Schrag; Julio Acosta-Cabronero; Geraint Rees; Huw R Morris; Rimona S Weil
Journal:  Brain       Date:  2018-09-01       Impact factor: 13.501

Review 10.  Merging Clinical and Imaging Biomarkers to Tackle Parkinson's Disease.

Authors:  Marina Picillo; Paolo Barone; Maria Teresa Pellecchia
Journal:  Mov Disord Clin Pract       Date:  2017-08-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.